Climb Bio, Inc. has made a significant update regarding its beneficial ownership in its latest SEC filing. The filing, submitted on November 5, 2026, reveals that FMR LLC holds a substantial stake in the company, which could influence Climb Bio's strategic direction moving forward.
Climb Bio, Inc. operates within the pharmaceutical preparations sector, classified under SIC code 2834. The company trades on the Nasdaq under the ticker symbol CLYM. Recent filings include a Schedule 13G/A, a registration statement (S-3ASR), and a quarterly report (10-Q), all filed on the same day, indicating a busy period for the company.
The recent Schedule 13G/A filing indicates that FMR LLC beneficially owns 8,615,432 shares of Climb Bio, representing approximately 15% of the company's outstanding common stock. Abigail P. Johnson, a key figure at FMR LLC, is also noted in the filing as holding the same number of shares, indicating a strong alignment between the investment firm and its leadership.
This update may have implications for various stakeholders, including shareholders and potential investors, as it highlights FMR LLC's significant influence over Climb Bio. The filing suggests that the Johnson family, through their ownership stakes, may form a controlling group within FMR LLC, which could further impact decision-making processes at Climb Bio.
What's next for Climb Bio remains unclear, as the filing does not specify any forthcoming actions or events. However, the heightened interest from FMR LLC could signal a strategic shift or new initiatives for the company in the competitive pharmaceutical preparations market.
Read Next
Sven-Olof Lindblad sells shares in Lindblad Expeditions
Zeo Energy CEO Timothy Bridgewater Acquires 107,955 Shares
Manthripragada Vijay Acquires Additional Shares in Onterris
Laws James Acquires Shares in Onterris, Inc. via RSUs
Eightco Holdings CEO Acquires 100,000 Shares of Stock
Eightco CFO Vroman Acquires 15,000 Shares in Stock Transaction





